ºÚÁÏÍø

Lymphoproliferative disorders (LPDs) encompass a range of conditions characterized by the abnormal growth of lymphoid cells. These disorders are of particular concern in post-transplant patients, especially following organ transplantation, where immunosuppressive therapy is necessary to prevent graft rejection. The prolonged use of immunosuppressive medications, while essential for maintaining organ function, increases the risk of developing malignancies, including LPDs. Post-transplant lymphoproliferative disorder (PTLD) is the most common type of LPD in transplant recipients, with a wide spectrum of clinical manifestations, ranging from benign lymphoid hyperplasia to aggressive lymphomas. Given the heterogeneous nature of PTLD, early detection and accurate staging are crucial for guiding therapy and improving patient outcomes. Radiological imaging plays a pivotal role in the diagnosis, evaluation, and management of LPDs in post-transplant patients. This article discusses the role of radiological imaging in the evaluation of Lymphoproliferative Disorders in post-transplant patients, emphasizing the advantages of various imaging modalities [1].

Pathophysiology and Types of Lymphoproliferative Disorders in Post-Transplant Patients

LPDs that occur in post-transplant patients are primarily driven by the dysregulated immune system resulting from immunosuppressive therapy. The most common LPD in this setting is PTLD, which can be classified into two broad categories: early and late PTLD. Early PTLD typically occurs within the first year after transplantation and is more likely to involve Epstein-Barr virus (EBV) infection, a factor that plays a central role in the pathogenesis of PTLD. Late PTLD, occurring after the first year, is often associated with the development of lymphoma and can be EBV-negative. The clinical presentation of PTLD is variable, with symptoms ranging from lymphadenopathy and fever to organ dysfunction and cachexia. In addition to PTLD, post-transplant patients are at risk for other types of LPDs, such as diffuse large B-cell lymphoma (DLBCL), Hodgkin lymphoma, and extranodal lymphomas, which can involve various organs, including the gastrointestinal tract, lungs, and central nervous system. Because LPDs can manifest in multiple forms and locations, an effective radiological approach is essential for detecting these disorders and assessing their extent [2].

Role of CT Imaging in the Diagnosis and Staging of LPDs

Computed tomography (CT) imaging is one of the most widely used modalities for detecting and staging LPDs in post-transplant patients due to its accessibility, rapid acquisition, and ability to visualize anatomical structures in detail. CT is particularly useful for assessing the extent of disease, evaluating organ involvement, and detecting lymphadenopathy, which is common in PTLD. On CT scans, enlarged lymph nodes are a hallmark of LPDs, with PTLD often presenting as localized or widespread lymphadenopathy. In some cases, the involvement of extranodal sites, such as the liver, spleen, or gastrointestinal tract, can also be identified [3]. CT imaging is also valuable for guiding biopsy procedures, which are crucial for confirming the diagnosis of LPDs. In cases of suspected PTLD, the use of contrast-enhanced CT can help delineate the relationship between the lymph nodes and adjacent structures, providing important information for planning surgical or radiological interventions. Moreover, CT imaging allows for the monitoring of treatment response, particularly in cases of lymphoma, where changes in lymph node size or extranodal involvement can indicate disease progression or remission [4 ]. However, CT has some limitations in the evaluation of LPDs, particularly in assessing the involvement of soft tissues or small lesions that may not be as well visualized on standard scans. Furthermore, while CT can provide important information regarding the anatomical extent of disease, it does not offer the same level of tissue characterization as other imaging modalities [5].

MRI in the Evaluation of LPDs

Magnetic resonance imaging (MRI) offers several advantages over CT in the evaluation of LPDs, particularly when it comes to soft tissue contrast and the evaluation of extranodal involvement. MRI is especially useful for assessing the central nervous system (CNS), where PTLD can present as a mass or infiltrative lesion. The high resolution and soft tissue contrast of MRI make it an ideal modality for identifying and characterizing CNS involvement in post-transplant patients with LPDs. On MRI, PTLD in the CNS typically presents as a well-defined or infiltrative mass that enhances with gadolinium contrast, often reflecting the aggressive nature of the disease [6]. In addition to CNS evaluation, MRI is also valuable for assessing the liver, spleen, and other abdominal organs, where LPDs may manifest as masses or infiltrative lesions. MRI provides superior contrast resolution compared to CT, allowing for better differentiation between normal and abnormal tissues. For example, the use of hepatobiliary-specific contrast agents can improve the detection of liver involvement in patients with PTLD. Another advantage of MRI is its ability to assess the functional characteristics of lesions. Techniques such as diffusion-weighted imaging (DWI) and dynamic contrast-enhanced MRI (DCE-MRI) can provide additional information on tissue cellularity and vascularity, which may help differentiate between benign and malignant lesions and aid in monitoring treatment response. However, MRI is generally more time-consuming and less accessible than CT, which may limit its use in some clinical settings [7].

Role of PET/CT in Assessing LPDs

Positron emission tomography (PET), particularly when combined with CT (PET/CT), has become an increasingly important tool for evaluating LPDs in post-transplant patients. PET imaging uses fluorodeoxyglucose (FDG), a radiolabeled glucose analog, to assess the metabolic activity of tissues. Since malignant lymphoid tissues, including those involved in PTLD, typically exhibit increased glucose metabolism, PET/CT can help identify areas of active disease, even in early stages, before they become visible on anatomical imaging. PET/CT has several advantages in the assessment of LPDs, including its ability to detect both nodal and extranodal involvement, assess the entire body for potential sites of disease, and evaluate the metabolic activity of lesions. This is particularly useful for staging purposes and for identifying patients with aggressive disease who may require more intensive therapy. Additionally, PET/CT can be used to monitor treatment response, with a decrease in FDG uptake indicating a favorable response to therapy [8]. However, PET/CT has some limitations in the evaluation of post-transplant patients. For example, it is less sensitive for detecting small lesions or low-grade LPDs and can sometimes produce false positives due to inflammation or infection, which is common in immunosuppressed patients. Despite these limitations, PET/CT remains an invaluable tool for the comprehensive evaluation of LPDs in post-transplant patients, particularly in cases of suspected or known PTLD.

Ultrasound and Other Imaging Modalities

Ultrasound (US) can be useful for detecting superficial lymphadenopathy and assessing abdominal or pelvic masses in post-transplant patients. While it is a non-invasive and cost-effective imaging modality, its utility in evaluating LPDs is limited due to its inability to provide detailed tissue characterization and its lower sensitivity compared to CT or MRI. Other imaging modalities, such as bone scintigraphy or endoscopic ultrasound, may be used in specific clinical scenarios, but they are generally less commonly employed for the routine evaluation of LPDs in post-transplant patients.

Conclusion

Radiological imaging plays a crucial role in the detection, evaluation, and management of lymphoproliferative disorders in post-transplant patients. Each imaging modality CT, MRI, PET/CT, and ultrasound offers distinct advantages and limitations, and a multimodal approach is often necessary for comprehensive evaluation. CT remains the primary imaging tool for detecting lymphadenopathy and extranodal involvement, while MRI provides superior soft tissue contrast for assessing CNS and organ involvement. PET/CT, with its ability to assess metabolic activity, is invaluable for staging, monitoring treatment response, and detecting early or low-volume disease. The use of these imaging techniques in combination allows for more accurate diagnosis, optimal staging, and tailored treatment strategies, ultimately improving outcomes for post-transplant patients with LPDs. As advances in imaging technology continue, these modalities will likely become even more refined, enhancing the ability to detect and manage lymphoproliferative disorders in this vulnerable patient population.

1. Hanauer SB, Sandborn WJ (2019) . Am J Gastroenterol 114: 529-554.

,

2. Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, et al. (2018) . Am J Gastroenterol 113: 481-517.

, ,

3. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, et al. (2018) . Lancet 390: 2769-2778.

, ,

4. Siva C, Brasington R, Totty W, Sotelo A, Atkinson J (2002) . J Rheumatol 29: 1088–1092.

,

5. Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L (2017) . Lancet 389: 1741-1755.

, ,

6. Baumgart DC, Sandborn WJ (2012) . Lancet 380: 1590-1605.

, ,

7. Khor B, Gardet A, Xavier RJ (2011) . Nature 474: 307-317.

, Google Scholar,

8. Dogramaci Y, Kalaci A, Sevinç TT, Atik E, Esen E,  et al. (2009) .J Am Podiatr Med Assoc 99: 153–156.

, ,